GO
| HSI1 | 24,557.04 | +108.09 | 178.17B |
| HSCEI1 | 8,265.81 | +5.66 | 57.75B |
| Back Zoom + Zoom - Block Traded | |
|
US FDA Requires New Safety Warnings on All GLP-1 Drugs Over Potential Increased Risk of Rare Eye Disease
2026-11-10 17:44:21 Danish "weight-loss miracle drug" maker Novo Nordisk rose 0.6% in early European trading on Tuesday. The US Food and Drug Administration (FDA) said on Monday (9th) that after finding evidence suggesting GLP-1 drugs may increase the risk of a rare eye disease, the agency has required all GLP-1 drugs to carry new safety warnings. The condition, known as non-arteritic anterior ischemic optic neuropathy (NAION), may lead to sudden vision loss. The disease is rare, and a causal relationship has not yet been established. The FDA said it has required all GLP-1 drug manufacturers to add warnings stating that the use of these drugs may be associated with an increased risk of NAION. NAION is a condition that may cause sudden vision decline, including permanent vision loss. It is caused by reduced blood flow to the front part of the optic nerve, although its underlying cause remains not fully understood. The FDA said all currently marketed GLP-1 products have reported NAION cases. Eli Lilly and Company (LLY.US) rose 0.4% in pre-market trading. (da/ad)~ AASTOCKS Financial News Website: www.aastocks.com This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. | |